Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
Abstract Hypomyopathic dermatomyositis (DM) presents with cutaneous lesions consistent with dermatomyositis but in the absence of clinically appreciable muscle weakness. The cutaneous manifestations are often refractory and more resistant to conventional therapy than concomitant muscle involvement....
Main Authors: | Miao Miao, Yuhui Li, Bo Huang, Jing He, Zhanguo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-07-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-020-00421-8 |
Similar Items
-
Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis
by: Zhaoling Wang, et al.
Published: (2022-09-01) -
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
by: Junmei Zhang, et al.
Published: (2023-10-01) -
Therapeutic options in refractory anti-MDA5 dermatomyositis triggered by SARS-CoV-2 infection
by: Elena Juganaru, et al.
Published: (2022-09-01) -
Refractory dermatomyositis responsive to anifrolumab
by: Phillip S. Ang, BA, et al.
Published: (2024-01-01) -
Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study
by: Yunzhi Zhufeng, et al.
Published: (2022-03-01)